Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

Similar articles for PubMed (Select 18471899)

1.

Antipsychotic drug action: antagonism, inverse agonism or partial agonism.

Strange PG.

Trends Pharmacol Sci. 2008 Jun;29(6):314-21. doi: 10.1016/j.tips.2008.03.009. Epub 2008 May 28. Review.

PMID:
18471899
3.

In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.

Jordan S, Regardie K, Johnson JL, Chen R, Kambayashi J, McQuade R, Kitagawa H, Tadori Y, Kikuchi T.

J Psychopharmacol. 2007 Aug;21(6):620-7. Epub 2006 Nov 8.

PMID:
17092971
5.

Aripiprazole acts as a selective dopamine D2 receptor partial agonist.

Wood M, Reavill C.

Expert Opin Investig Drugs. 2007 Jun;16(6):771-5. Review.

PMID:
17501690
6.

[Pharmacology of antipsychotic drugs]].

Bourin M.

Encephale. 2006 Jan;32 Pt 2:S8-9. French. No abstract available.

PMID:
16800078
7.

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.

Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB.

J Pharmacol Exp Ther. 2002 Jul;302(1):381-9.

8.

Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.

Tadori Y, Forbes RA, McQuade RD, Kikuchi T.

Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40. doi: 10.1016/j.ejphar.2009.02.007. Epub 2009 Feb 13.

PMID:
19217900
9.

[Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].

Tadori Y, Kikuchi T.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2012 Feb;32(1):9-18. Review. Japanese.

PMID:
22568121
10.

Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors.

Tadori Y, Forbes RA, McQuade RD, Kikuchi T.

Eur J Pharmacol. 2008 Nov 12;597(1-3):27-33. doi: 10.1016/j.ejphar.2008.09.008. Epub 2008 Sep 20.

PMID:
18831971
11.

Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.

Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G, Fazekas K, Hornok K, Orosz S, Gyertyán I, Agai-Csongor E, Domány G, Tihanyi K, Adham N, Szombathelyi Z.

J Pharmacol Exp Ther. 2010 Apr;333(1):328-40. doi: 10.1124/jpet.109.160432. Epub 2010 Jan 21.

12.

Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?

Kessler RM.

Am J Psychiatry. 2007 Sep;164(9):1310-2. No abstract available.

PMID:
17728411
13.

Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912.

Tadori Y, Kitagawa H, Forbes RA, McQuade RD, Stark A, Kikuchi T.

Eur J Pharmacol. 2007 Nov 28;574(2-3):103-11. Epub 2007 Aug 10.

PMID:
17692841
14.
15.

Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.

Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S.

Am J Psychiatry. 2007 Sep;164(9):1411-7.

PMID:
17728427
16.

Dopamine partial agonists: a new class of antipsychotic.

Lieberman JA.

CNS Drugs. 2004;18(4):251-67. Review.

PMID:
15015905
17.

[A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists].

Costentin J.

Ann Pharm Fr. 2009 Sep;67(5):310-9. doi: 10.1016/j.pharma.2009.05.004. Epub 2009 Jul 18. Review. French.

PMID:
19695367
18.

Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.

Keck PE Jr, McElroy SL.

Expert Opin Investig Drugs. 2003 Apr;12(4):655-62. Review.

PMID:
12665420
19.

Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation.

Etievant A, Bétry C, Arnt J, Haddjeri N.

Neurosci Lett. 2009 Aug 21;460(1):82-6. doi: 10.1016/j.neulet.2009.05.035. Epub 2009 May 18.

PMID:
19450663
20.

Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.

Cosi C, Carilla-Durand E, Assié MB, Ormiere AM, Maraval M, Leduc N, Newman-Tancredi A.

Eur J Pharmacol. 2006 Mar 27;535(1-3):135-44. Epub 2006 Mar 22.

PMID:
16554049
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk